Breast cancer: TNBC: can we treat the untargetable?
Lisa
L
Hutchinson
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016190:Carboplatin; D018719:Erb-b2 Receptor Tyrosine Kinases